Research Progress in the Treatment of Diabetes Mellitus with Cardiovascular Complications with Sacubitril Valsartan

Lin CHEN; Xin NIAN; Hongyan CAI

doi:10.12259/j.issn.2095-610X.S20241101

Volume 45 Issue 11

Nov. 2024

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2024 > 45(11): 155-160

Lin CHEN, Xin NIAN, Hongyan CAI. Research Progress in the Treatment of Diabetes Mellitus with Cardiovascular Complications with Sacubitril Valsartan[J]. Journal of Kunming Medical University, 2024, 45(11): 155-160. doi: 10.12259/j.issn.2095-610X.S20241101

Citation:

Lin CHEN, Xin NIAN, Hongyan CAI. Research Progress in the Treatment of Diabetes Mellitus with Cardiovascular Complications with Sacubitril Valsartan[J]. Journal of Kunming Medical University, 2024, 45(11): 155-160. doi: 10.12259/j.issn.2095-610X.S20241101

Citation:

PDF( 571 KB)

Research Progress in the Treatment of Diabetes Mellitus with Cardiovascular Complications with Sacubitril Valsartan

doi: 10.12259/j.issn.2095-610X.S20241101

Lin CHEN¹,
Xin NIAN^{1
,
,},
Hongyan CAI²

1.
Dept. of Endocrinology
2.
Dept 2. of Cardiology，The 1st Affiliated Hospital of Kunming Medical University，Kunming Yunnan 650032，China

Received Date: 2024-10-22
Available Online: 2024-11-18
Publish Date: 2024-11-25

Abstract

Abstract

Diabetes often coexists with cardiovascular complications, which are also a common cause of death in diabetes patients. Therefore, in addition to improving glucose metabolism, it is also necessary to control cardiovascular complications in diabetes patients. Sacubitril valsartan is a novel compound with dual actions of inhibiting neprilysin and angiotensin receptor, and it is commonly used as a heart failure drug in clinical practice. Recent studies suggest that sacubitril valsartan may also have potential metabolic benefits, improving cardiac function while improving glycemic control in diabetes patients, and it is expected to become a drug that can be used routinely in diabetes, bringing cardiovascular and metabolic benefits. This review focuses on the clinical efficacy and metabolic benefits of sacubitril valsartan in the treatment of diabetes patients with cardiovascular diseases.
- Sacubitril valsartan,
- Neprilysin,
- Renin angiotensin system,
- Natriuretic peptide,
- Blood sugar

FullText(HTML)

References(33)

References

[1]	李智宁,潘志琼. 沙库巴曲缬沙坦治疗慢性心力衰竭合并糖尿病患者的临床研究[J]. 糖尿病新世界,2022,25(10):69-72.
[2]	王险峰,徐涛. 沙库巴曲缬沙坦钠治疗心力衰竭伴2型糖尿病的临床效果[J]. 临床医学研究与实践,2019,4(14):50-51.
[3]	刘洋,吕媛媛. 替米沙坦与缬沙坦对原发性高血压病人胰岛素抵抗的影响[J]. 中西医结合心脑血管病杂志,2017,15(13):1615-1618. doi: 10.3969/j.issn.1672-1349.2017.13.023
[4]	Malek V,Gaikwad A B. Neprilysin inhibitors: A new hope to halt the diabetic cardiovascular and renal complications[J]. Biomed Pharmacother,2017,90(6):752-759.
[5]	史云聪,和丽丽,白晓谊. 肾素-血管紧张素系统及脑啡肽酶抑制剂临床应用进展[J]. 临床荟萃,2020,35(5):476-480. doi: 10.3969/j.issn.1004-583X.2020.05.019
[6]	Abuissa H,Jones P G,Marso S P,et al. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: A meta-analysis of randomized clinical trials[J]. J Am Coll Cardiol,2005,46(5):821-826. doi: 10.1016/j.jacc.2005.05.051
[7]	Zhang Z,Liu C,Gan Z,et al. Improved glucose-stimulated insulin secretion by selective intraislet inhibition of angiotensin II type 1 receptor expression in isolated islets of db/db mice[J]. Int J Endocrinol,2013,2013:319586.
[8]	Carlsson P O,Berne C,Jansson L. Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats[J]. Diabetologia,1998,41(2):127-133. doi: 10.1007/s001250050880
[9]	马妮娜,沈潞华. 氯沙坦对高血糖合并高血压患者胰岛素敏感性的影响[J]. 临床合理用药杂志,2011,4(28):20-22.
[10]	潘利亚,张晓卉,尹新华. 糖尿病心肌病发病机制的研究进展[J]. 中国心血管杂志,2017,22(2):143-146. doi: 10.3969/j.issn.1007-5410.2017.02.015
[11]	Rubattu S,Gallo G. The natriuretic peptides for hypertension treatment[J]. High Blood Press Cardiovasc Prev,2022,29(1):15-21. doi: 10.1007/s40292-021-00483-5
[12]	杨淑莲,吴晓羽. 沙库巴曲缬沙坦的临床应用及其潜在作用[J]. 实用心脑肺血管病杂志,2020,28(5):82-86. doi: 10.3969/j.issn.1008-5971.2020.05.016
[13]	Jordan J,Stinkens R,Jax T,et al. Improved insulin sensitivity with angiotensin receptor neprilysin inhibition in individuals with obesity and hypertension[J]. Clin Pharmacol Ther,2017,101(2):254-263. doi: 10.1002/cpt.455
[14]	Cloro C,Zaffina I,Sacchetta L,et al. Effects of sacubitril/valsartan on both metabolic parameters and insulin resistance in prediabetic non-obese patients with heart failure and reduced ejection fraction[J]. Front Endocrinol (Lausanne),2022,13(10):1-9. doi: 10.3389/fendo.2022.940654
[15]	赵刚,张虹. 沙库巴曲缬沙坦应用于心血管疾病研究进展[J]. 安徽医药,2020,24(7):1273-1277. doi: 10.3969/j.issn.1009-6469.2020.07.001
[16]	Przezak A,Bielka W,Pawlik A. Hypertension and type 2 diabetes-the novel treatment possibilities[J]. Int J Mol Sci,2022,23(12):1-16.
[17]	Campbell D J. Long-term neprilysin inhibition - implications for ARNIs[J]. Nat Rev Cardiol,2017,14(3):171-186. doi: 10.1038/nrcardio.2016.200
[18]	Seferovic J P,Solomon S D,Seely E W. Potential mechanisms of beneficial effect of sacubitril/valsartan on glycemic control[J]. Ther Adv Endocrinol Metab,2020,11(24):1-9.
[19]	杨庭树. 慢性心力衰竭药物治疗的历程与进展[J]. 中华保健医学杂志,2022,24(2):81-86. doi: 10.3969/j.issn.1674-3245.2022.02.001
[20]	费美莹,姜东炬. 心力衰竭药物沙库巴曲缬沙坦的研究进展[J]. 心血管病学进展,2020,41(2):122-125.
[21]	Gamarra E,Baffoni C,Borretta G,et al. Reduction of insulin requirement after starting treatment with sacubitril/valsartan in a patient with diabetes treated with continuous subcutaneous insulin infusion (CSII): A case report[J]. J Diabetes Sci Technol,2018,12(6):1254-1255. doi: 10.1177/1932296818785644
[22]	Packer M. Augmentation of glucagon-like peptide-1 receptor signalling by neprilysin inhibition: potential implications for patients with heart failure[J]. Eur J Heart Fail,2018,20(6):973-977. doi: 10.1002/ejhf.1185
[23]	Seferovic J P,Claggett B,Seidelmann S B,et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: A post-hoc analysis from the PARADIGM-HF trial[J]. Lancet Diabetes Endocrinol,2017,5(5):333-340. doi: 10.1016/S2213-8587(17)30087-6
[24]	de la Espriella-Juan R,Sanchis J,Bayes-Genis A,et al. Metabolic effects of sacubitril/valsartan: Are they relevant in clinical practice?[J]. Cardiovasc Diagn Ther,2018,8(4):549-551. doi: 10.21037/cdt.2018.07.05
[25]	van der Zijl N J,Moors C C,Goossens G H,et al. Valsartan improves beta-cell function and insulin sensitivity in subjects with impaired glucose metabolism: A randomized controlled trial[J]. Diabetes Care,2011,34(4):845-851. doi: 10.2337/dc10-2224
[26]	Bindom S M,Lazartigues E. The sweeter side of ACE2: Physiological evidence for a role in diabetes[J]. Mol Cell Endocrinol,2009,302(2):193-202. doi: 10.1016/j.mce.2008.09.020
[27]	Zhang Z,Liu C,Gan Z,et al. Improved glucose-stimulated insulin secretion by selective intraislet inhibition of angiotensin II type 1 receptor expression in isolated islets of db/db mice[J]. Int J Endocrinol,2013,2013(1):1-10.
[28]	Cole B K,Keller S R,Wu R,et al. Valsartan protects pancreatic islets and adipose tissue from the inflammatory and metabolic consequences of a high-fat diet in mice[J]. Hypertension,2010,55(3):715-721. doi: 10.1161/HYPERTENSIONAHA.109.148049
[29]	McMurray J J,Holman R R,Haffner S M,et al. Effect of valsartan on the incidence of diabetes and cardiovascular events[J]. N Engl J Med,2010,362(16):1477-1490. doi: 10.1056/NEJMoa1001121
[30]	Zimmet P,Alberti K G,Magliano D J,et al. Diabetes mellitus statistics on prevalence and mortality: Facts and fallacies[J]. Nat Rev Endocrinol,2016,12(10):616-622. doi: 10.1038/nrendo.2016.105
[31]	McMurray J J,Gerstein H C,Holman R R,et al. Heart failure: A cardiovascular outcome in diabetes that can no longer be ignored[J]. Lancet Diabetes Endocrinol,2014,2(10):843-851. doi: 10.1016/S2213-8587(14)70031-2
[32]	Wang R,Ye H,Zhao Y,et al. Effect of sacubitril/valsartan and ACEI/ARB on glycaemia and the development of diabetes: A systematic review and meta-analysis of randomised controlled trials[J]. BMC Med,2022,20(1):487. doi: 10.1186/s12916-022-02682-w
[33]	Esser N,Schmidt C,Barrow B M,et al. Insulinotropic effects of neprilysin and/or angiotensin receptor inhibition in mice[J]. Front Endocrinol (Lausanne),2022,13(6):1-14.

Relative Articles(20)

Relative Articles

[1]	Murong JIANG, Yuanqin LEI, Ke ZHANG, Qiumei LIU, Wenli YANG, Hongyi LIU, Jie YAN, Qingwen ZHANG. Study on the Influence of Yunnan Rice Products on Blood Sugar. Journal of Kunming Medical University, 2023, 44(12): 41-45. doi: 10.12259/j.issn.2095-610X.S20231207
[2]	Meng SHANG, Xiaolong GAO, Xiaohui KUANG, Xi ZHANG, Jin ZHANG, Lilin WANG. Application of Sacubitril/valsartan in Patients with Chronic Heart Failure Implanted with Implantable Cardioverter Defibrillators. Journal of Kunming Medical University, 2023, 44(11): 63-69. doi: 10.12259/j.issn.2095-610X.S20231109
[3]	Yanfei WANG, Juan MA, Yunqiao YANG. Clinical Efficacy and Safety of Sacubatril Valsartan in Patients with Reduced Ejection Fraction Combined with Hypotensive Heart Failure. Journal of Kunming Medical University, 2022, 43(11): 136-140. doi: 10.12259/j.issn.2095-610X.S20221117
[4]	Yong YUAN, Xinyi LI, Yan FU, Yan ZHU. Analysis of Vitamin D Level in Pregnant Women and Infants in Kunming and Study on the Relationship between Fasting Blood Glucose Level and Vitamin D Level during Pregnancy. Journal of Kunming Medical University, 2022, 43(9): 125-129. doi: 10.12259/j.issn.2095-610X.S20220931
[5]	Zhang Ti Ling , Zhang Wei Hua , Luo Qing 祎, Xia Hong Ying , Lu Yi Bing . . Journal of Kunming Medical University, 2020, 41(03): 91-95.
[6]	Wang Li Li . . Journal of Kunming Medical University, 2019, 40(05): 117-121.
[7]	Lin Yi Lin , Zhang Hong , Ding Xiao Xue . . Journal of Kunming Medical University, 2019, 40(05): 1-4.
[8]	Zhu Li , Qiu Hong Mei , Zhou Xiao Fang , Cai Hai Gang , Liu Kai Ping , Zhou Yuan Yuan . . Journal of Kunming Medical University, 2018, 39(11): 83-86.
[9]	Su Hong , Sun Hong Li , Yang Jun . . Journal of Kunming Medical University, 2018, 39(09): 33-36.
[10]	Yang Ping . . Journal of Kunming Medical University,
[11]	Chang Lu . . Journal of Kunming Medical University,
[12]	Fu Zhong Yang . . Journal of Kunming Medical University,
[13]	Zhang Hong . . Journal of Kunming Medical University,
[14]	Yang Li Wei . . Journal of Kunming Medical University,
[15]	Yang Qiu Ping . . Journal of Kunming Medical University, 2014, 35(09): 1-1.
[16]	Xiong Yu Xin . . Journal of Kunming Medical University,
[17]	Chang Li Xia . . Journal of Kunming Medical University,
[18]	Zeng Xi Yun . . Journal of Kunming Medical University,
[19]	Wei Meng Nan . . Journal of Kunming Medical University,
[20]	Chen Guan Fen . Clinical Significance of Serum Procalcitonin Levels in Optimizing Antibiotic Therapy for Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Journal of Kunming Medical University,